

Independent Auditor's Report

To the Members of **Fermenta Biotech Limited**

Report on the Standalone Financial Statements

We have audited the accompanying standalone financial statements of Fermenta Biotech Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2017, the Statement of Profit and Loss and Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the Companies (Accounting Standards) Amendment Rules, 2016. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder. We conducted our audit in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the

audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at March 31, 2017, its profit, and its cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure 1 a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by section 143 (3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - (b) In our opinion proper books of account as required by law

have been kept by the Company so far as it appears from our examination of those books;

- (c) The Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;
- (d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the Companies (Accounting Standards) Amendment Rules, 2016;
- (e) On the basis of written representations received from the directors as on March 31, 2017, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2017, from being appointed as a director in terms of section 164 (2) of the Act;
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure 2" to this report;
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements – Refer Note 31 to the standalone financial

statements;

- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv. The Company has provided requisite disclosures in Note 41 to these standalone financial statements as to the holding of Specified Bank Notes on November 8, 2016 and December 30, 2016 as well as dealings in Specified Bank Notes during the period from November 8, 2016 to December 30, 2016. Based on our audit procedures and relying on the management representation regarding the holding and nature of cash transactions, including Specified Bank Notes, we report that these disclosures are in accordance with the books of accounts maintained by the Company and as produced to us by the Management.

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003

per **Vikram Mehta**

Partner

Place: Mumbai

Date: May 30, 2017

Membership Number: 105938

Annexure 1 – Statement on matters specified in paragraphs 3 and 4 of the Companies (Auditor’s Report) Order, 2017

- (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
- (b) All fixed assets have not been physically verified by the management during the year but there is a regular programme of verification which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.
- (c) According to the information and explanations given by the management, the title deeds of immovable properties included in property, plant and equipment are held in the name of the Company.
- (ii) The inventory has been physically verified by the management during the year. In our opinion, the frequency of verification is reasonable. No material discrepancies were noticed on such physical verification. Inventories lying with third parties have been confirmed by them as at the year end and no material discrepancies were noticed in respect of such confirmations.
- (iii) (a) According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under section 189 of the Companies Act, 2013. Accordingly, the provisions of clause 3(iii)(a), (b) and (c) of the Order are not applicable to the Company and hence not commented upon.
- (iv) In our opinion and according to the information and explanations given to us, there are no loans, investments, guarantees, and securities given in respect of which provisions of section 185 and 186 of the Companies Act 2013 are applicable and, hence, not commented upon.
- (v) The Company has not accepted any deposits from the public.
- (vi) We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under section 148(1) of the Companies Act, 2013, related to the manufacture of bulk drugs and formulations, and are of the opinion that prima facie, the specified accounts and records have been made and maintained. We have not, however, made a detailed examination of the same.
- (vii) (a) The Company is regular in depositing with appropriate authorities undisputed statutory dues including provident fund, employees’ state insurance, income-tax, sales-tax, service tax, duty of custom, duty of excise, value added tax, cess and other statutory dues applicable to it.
- (b) According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees’ state insurance, income-tax, service tax, sales-tax, duty of custom, duty of excise, value added tax, cess and other statutory dues were outstanding, at the year end, for a period of more than six months from the date they became payable.
- (c) According to the information and explanations given to us, there are no dues of income tax, sales-tax, service tax, customs duty, excise duty, value added tax and cess which have not been deposited on account of any dispute.
- (viii) In our opinion and according to the information and explanations given by the management, the Company has not defaulted in repayment of loans or borrowing to a financial institution, bank or government or dues to debenture holders.
- (ix) In our opinion and according to the information and explanations given by the management, the Company has utilized the monies raised by way of term loans for the purposes for which they were raised.
- (x) Based upon the audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to the information and explanations given by the management, we report that no fraud by the Company or no fraud on the Company by the officers and employees of the Company has been noticed or reported during the year.
- (xi) According to the information and explanations given by the management, the managerial remuneration has been paid / provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act, 2013.
- (xii) In our opinion, the Company is not a nidhi company. Therefore, the provisions of clause 3(xii) of the order are not applicable

to the Company and hence not commented upon.

(xiii) According to the information and explanations given by the management, transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the financial statements, as required by the applicable accounting standards.

(xiv) According to the information and explanations given by management to us and on an overall examination of the balance sheet, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review and hence, reporting requirements under clause 3(xiv) are not applicable to the Company and, not commented upon.

(xv) According to the information and explanations given by the

management, the Company has not entered into any non-cash transactions with directors or persons connected with him as referred to in section 192 of Companies Act, 2013.

(xvi) According to the information and explanations given to us, the provisions of section 45-IA of the Reserve Bank of India Act, 1934 are not applicable to the Company.

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003

per **Vikram Mehta**

Partner

Place: Mumbai

Date: May 30, 2017

Membership Number: 105938

Annexure 2 – To the independent auditor's report of even date on the standalone financial statements of Fermenta Biotech Limited

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of Fermenta Biotech Limited ("the Company") as of March 31, 2017 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing as specified under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence

about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to

error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2017, based on the internal control over

financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003

per **Vikram Mehta**

Partner

Place: Mumbai

Date: May 30, 2017

Membership Number: 105938

CIN : U99999MH1986PLC134021

Balance Sheet as at March 31, 2017

(₹ in Lakhs)

Particulars	Note No.	March 31, 2017	March 31, 2016
Equity and liabilities			
Shareholders' funds			
Share capital	3	1,770.45	1,770.45
Reserves and surplus	4	8,269.91	7,280.62
		10,040.36	9,051.07
Non current liabilities			
Long term borrowings	5	606.46	363.34
Deferred tax liability (net)	6	272.48	399.53
Long term provisions	7	192.45	143.76
		1,071.39	906.63
Current liabilities			
Short term borrowings	8	3,363.02	2,847.21
Trade payables	9		
• Total outstanding dues of micro enterprises and small enterprises		20.20	5.14
• Total outstanding dues of creditors other than micro enterprises and small enterprises		2,699.01	1,798.42
Other current liabilities	9	676.14	976.95
Short term provisions	7	61.72	189.98
		6,820.09	5,817.70
TOTAL		17,931.84	15,775.40
Assets			
Non current assets			
Fixed assets			
Property, Plant and Equipment	10	7,423.48	6,804.85
Intangible assets	11	50.12	80.48
Capital work in progress		276.46	533.37
Intangible assets under development		142.52	3.00
Non current investments	12	186.62	186.62
Long term loans and advances	13	358.02	357.01
Other non current assets	14.2	-	0.70
		8,437.22	7,966.03
Current assets			
Inventories	15	3,874.59	2,483.78
Trade receivables	14.1	4,462.19	4,338.29
Other current assets	14.2	481.24	364.69
Cash and bank balances	16	114.49	84.49
Short term loans and advances	13	562.11	538.12
		9,494.62	7,809.37
TOTAL		17,931.84	15,775.40
Summary of significant accounting policies			
	2.1		
The accompanying notes are an integral part of the standalone financial statements			

As per our report of even date

For and on behalf of the Board of Directors of
Fermenta Biotech LimitedFor S R B C & CO LLP
ICAI Firm Registration Number: 324982E / E300003
Chartered AccountantsPeter Bains
ChairmanSatish Varma
Managing DirectorKrishna Datla
Directorper Vikram Mehta
Partner
Membership No.: 105938Sanjay Buch
DirectorAnupama Datla Desai
Executive DirectorViswanath Chibrolu
DirectorGopakumar Nair
DirectorVaradvinayak Khambete
Company SecretaryKapil Gohil
Chief Financial OfficerPlace: Mumbai
Date : May 30, 2017Place: Thane
Date : May 30, 2017

CIN : U99999MH1986PLC134021

Statement of Profit & Loss for the year ended March 31, 2017

(₹ in Lakhs)

Particulars	Note No.	March 31, 2017	March 31, 2016
Income			
Revenue from operations (gross)	17	16,078.40	15,004.36
Less : excise duty		155.89	294.77
Revenue from operations (net)		15,922.51	14,709.59
Other income	18	232.36	269.53
Total Revenue	(I)	16,154.87	14,979.12
Expenses			
Cost of materials consumed	19	7,599.30	6,284.83
Purchase of traded goods	19	22.21	160.11
(Increase) / decrease in the inventory of finished goods and work-in-progress	20	(789.44)	(53.06)
Employee benefit expense	21	2,259.36	2,036.28
Depreciation and amortization expense	22	672.41	646.74
Finance costs	23	362.34	454.62
Other expenses	24	4,799.98	3,832.06
Total	(II)	14,926.16	13,361.58
Profit before prior period item and tax (I-II)	(III)	1,228.71	1,617.54
Prior period item		17.07	-
Profit before tax		1,211.64	1,617.54
Tax expense:			
Current tax		349.40	345.21
Deferred tax charge		(127.05)	83.41
Total tax expense		222.35	428.62
Profit after tax		989.29	1,188.92
Earnings per equity share (nominal value of share ₹10) (2016: ₹10)	25		
(1) Basic		5.44	6.54
(2) Diluted		5.44	6.54
Summary of significant accounting policies	2.1		
The accompanying notes are an integral part of the standalone financial statements			

As per our report of even date

For S R B C & CO LLP
ICAI Firm Registration Number: 324982E / E300003
Chartered Accountants

per Vikram Mehta
Partner
Membership No.: 105938

Place: Mumbai
Date : May 30, 2017

For and on behalf of the Board of Directors of
Fermenta Biotech Limited

Peter Bains Chairman	Satish Varma Managing Director	Krishna Datla Director
Sanjay Buch Director	Anupama Datla Desai Executive Director	Viswanath Chibrolu Director
Gopakumar Nair Director	Varadvinayak Khambete Company Secretary	Kapil Gohil Chief Financial Officer

Place: Thane
Date : May 30, 2017

Cash Flow Statement for the year ended March 31, 2017

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	1,211.64	1,617.54
Adjustment to reconcile profit before tax to net cash flows		
Depreciation / amortizations	672.41	646.74
Foreign exchange (gain)/loss (net) - unrealized	(48.90)	(52.78)
Loss / (Profit) on sale of fixed assets (net)	9.05	(0.70)
Provision for doubtful debts and advances	425.54	9.63
Interest expense	379.41	454.62
Dividend Income	(0.20)	(0.20)
Interest income	(20.98)	(3.14)
Operating profit before working capital changes	2,627.97	2,671.71
Movements in working capital:		
Increase/ (Decrease) in trade payables	953.30	302.26
Increase/ (Decrease) in long term provisions	48.69	9.03
Increase/ (Decrease) in short term provisions	(1.44)	4.26
Increase/ (Decrease) in other current liabilities	(75.83)	108.07
(Increase)/ Decrease in trade receivables	(575.78)	(743.77)
(Increase)/ Decrease in inventories	(1,390.81)	(381.61)
(Increase)/ Decrease in long term loans and advances	(3.32)	8.12
(Increase)/ Decrease in short term loans and advances	(115.92)	(136.00)
(Increase)/ Decrease in other current assets	(116.55)	(351.12)
(Increase)/ Decrease in other non-current assets	-	14.34
Cash generated from operations	1,350.31	1,505.29
Direct taxes paid (net of refunds)	(406.91)	(191.95)
Net cash flow from operating activities	943.40	1,313.34
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of fixed assets (including intangible assets, adjustments for capital work-in-progress and capital advances)	(1,093.89)	(819.20)
Proceeds from sale of fixed assets	1.11	0.93
Investment in bank deposits having maturity of more than three months	0.70	(13.36)
Dividend received	0.20	0.20
Interest received	8.74	3.14
Net cash used in investing activities	(1,083.14)	(828.29)

CIN : U99999MH1986PLC134021

Cash Flow Statement for the year ended March 31, 2017

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from long term borrowings	584.49	473.86
Repayment of long term borrowings	(608.97)	(561.62)
Net Proceeds from short term borrowings	565.58	109.95
Interest paid	(371.38)	(457.10)
Net cash flow (used in)/from financing activities	169.72	(434.91)
Net increase in Cash and Cash equivalents	29.98	50.14
Effect of exchange differences on cash & cash equivalents held in foreign currency	0.02	-
Cash and Cash equivalents at the beginning of the year	84.49	34.35
Cash and Cash equivalents at the end of the year	114.49	84.49
Components of Cash and Cash equivalents		
Cash on hand	6.42	3.64
Balances with banks on:		
Current accounts	108.04	80.82
Deposit accounts	0.03	0.03
Total cash and cash equivalents (note 16)	114.49	84.49

Notes:

- Cash flow statement has been prepared under indirect method as set out in the Accounting Standard (AS-3) "Cash Flow Statements" as specified in Companies (Accounts) Rules, 2014.
- Previous year's figures have been regrouped/rearranged wherever necessary.

Summary of significant accounting policies	2.1		
---	------------	--	--

As per our report of even date

For S R B C & CO LLP
ICAI Firm Registration Number: 324982E / E300003
Chartered Accountants

per Vikram Mehta
Partner
Membership No.: 105938

Place: Mumbai
Date : May 30, 2017

For and on behalf of the Board of Directors of
Fermenta Biotech Limited

Peter Bains Chairman	Satish Varma Managing Director	Krishna Datla Director
-------------------------	-----------------------------------	---------------------------

Sanjay Buch Director	Anupama Datla Desai Executive Director	Viswanath Chibrolu Director
-------------------------	---	--------------------------------

Gopakumar Nair Director	Varadvinayak Khambete Company Secretary	Kapil Gohil Chief Financial Officer
----------------------------	--	--

Place: Thane
Date : May 30, 2017

Notes to Financial Statements for the year ended March 31, 2017

1 Background:

Fermenta Biotech Limited ("the Company") is a public company domiciled in India and incorporated under the Companies Act, 1956. The Company is engaged in the business of manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations and environmental solution products. The Company caters to both domestic and international markets.

2 Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP). The financial statements have been prepared to comply in all material respects with the accounting standards notified under section 133 of the Companies Act, 2013, read together with paragraph 7 of Companies (Accounts) Rules, 2014 and Companies (Accounting Standards) Amendment Rules, 2016. The financial statements have been prepared on an accrual basis and under the historical cost convention.

The accounting policies adopted in the preparation of financial statements are consistent with those of previous year.

2.1 Summary of significant accounting policies:

a) Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting period end. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates.

b) Property, Plant & Equipment

Property, plant and equipment, capital work in progress are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met, directly attributable cost of bringing the asset to its working condition for the intended use and initial estimate of decommissioning, restoring and similar liabilities. Any trade discounts and rebates are deducted in arriving at the purchase price. Such cost includes the cost of replacing part of the plant and equipment. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in profit or loss as incurred.

Items of stores and spares that meet the definition of property, plant and equipment are capitalized at cost and depreciated over their useful life. Otherwise, such items are classified as inventories.

Gains or losses arising from derecognition of property, plant and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

The Company identifies and determines cost of each component/ part of the asset separately, if the component/ part has a cost which is significant to the total cost of the asset and has useful life that is materially different from that of the remaining asset.

c) Depreciation on Property, Plant & Equipment

Depreciation on property, plant and equipment is calculated on a straight-line basis using the rates arrived at based on the useful lives estimated by the management. The identified components are depreciated over their useful lives; the remaining components

Notes to Financial Statements for the year ended March 31, 2017

are depreciated over the life of the principal asset. The Company has used the following useful lives to provide depreciation on its property, plant and equipment.

Assets	Estimated useful life (in years)
Lease hold land	30
Building	30
Lease hold improvements (included in buildings)	10
Plant and equipment	10-20
Office equipments	5
Computers	3-6
Furniture and fixtures	10
Vehicles	8

d) Intangible Assets

Intangible assets acquired separately are measured on initial recognition at cost. Intangible assets are amortized on a straight line basis over the estimated useful economic life.

The amortisation period and the amortisation method are reviewed at least at each financial year end. If the expected useful life of the asset is significantly different from previous estimates, the amortisation period is changed accordingly. If there has been a significant change in the expected pattern of economic benefits from the asset, the amortisation method is changed to reflect the changed pattern. Such changes are accounted for in accordance with AS 5 "Net Profit or Loss for the Period, Prior Period Items and Changes in Accounting Policies".

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

The Company has used the following useful lives to provide depreciation on its intangible assets.

Assets	Estimated useful life (in years)
Software including licences	6
Product know how	3 - 5

Research and Development Costs

Research costs are expensed as incurred. Development expenditure incurred on an individual project is recognized as an intangible asset when the Company can demonstrate: (i) the technical feasibility of completing the intangible asset so that it will be available for use or sale; (ii) its intention to complete the asset and use or sell it; (iii) its ability to use or sell the asset; (iv) how the asset will generate probable future economic benefits; (v) the availability of adequate resources to complete the development and to use or sell the asset; and (vi) the ability to measure reliably the expenditure attributable to the intangible asset during development.

Any expenditure so capitalized is amortized over their estimated useful lives of three to five years on a straight line basis.

The carrying value of development costs is reviewed for impairment annually when the asset is not yet in use, and otherwise when events or changes in circumstances indicate that the carrying value may not be recoverable.

e) Impairment of fixed assets

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) net selling price and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those

Notes to Financial Statements for the year ended March 31, 2017

from other assets or groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining net selling price, recent market transactions are taken into account, if available. If no such transactions can be identified, an appropriate valuation model is used.

After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

An assessment is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the Company estimates the asset's or cash-generating unit's recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the statement of profit and loss.

f) Investments

Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as long-term investments.

Current investments are carried in the financial statements at lower of cost and fair value determined on an individual investment basis. Long-term investments are carried at cost. However, provision for diminution in value is made to recognize a decline other than temporary in the value of the investments.

On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss.

g) Inventories

Inventories are stated at lower of cost and net realisable value. However, materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost.

Cost is determined as follows:

- (a) Stores and spare parts: - First-in-first-out method.
Stores and spares which do not meet the definition of property, plant and equipment are accounted as inventories.
- (b) Raw materials and packing materials: - Cost is determined on a weighted average basis.
- (c) Intermediate raw materials, work-in-process and finished goods:- Cost includes direct materials determined on the basis of weighted average method and labour and a proportion of manufacturing overheads based on normal operating capacity.
Cost of finished goods includes excise duty.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

h) Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognized:

Sale of Goods

Revenue from sale of goods is recognized when all the significant risks and rewards of ownership of the goods have been passed to the buyer. The Company collects sales taxes and value added taxes (VAT) on behalf of the government and, therefore, these are not economic benefits flowing to the Company. Hence, they are excluded from revenue. Excise duty deducted from revenue (gross) is the amount that is included in the revenue (gross) and not the entire amount of liability arising during the year.

Notes to Financial Statements for the year ended March 31, 2017

Income from services

Revenues from environmental project consultancy contracts are recognized pro-rata over the period of the contract as and when services are rendered. The Company collects service tax on behalf of the government and, therefore, it is not an economic benefit flowing to the Company. Hence, it is excluded from revenue.

Interest

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "other income" in the statement of profit and loss.

Export Incentive

Duty free imports of raw materials under Advance License for imports as per the Import and Export Policy are matched with the exports made against the said licenses and net benefit / obligation is accounted by making suitable adjustments in raw material consumption.

The benefit accrued under the Duty Drawback, Merchantile Export Incentive Scheme and other schemes as per the Import and Export policy in respect of exports made under the said schemes is included as 'Export Incentives' under the note "other operating revenue" in the statement of profit and loss.

i) Foreign currency transactions

Initial Recognition

Transactions in foreign currencies are recorded in the reporting currency at the exchange rate prevailing between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; and non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.

Exchange Differences

Exchange differences arising on the settlement of monetary items or on reporting monetary items of Company at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognised as income or as expenses in the year in which they arise except those arising from investments in non-integral operations.

Forward Exchange Contracts not intended for trading or speculation purposes

The premium or discount arising at the inception of forward exchange contracts is amortized as expense or income over the life of the contract. Exchange differences on such contracts are recognised in the statement of profit and loss in the year in which the exchange rates change. Any profit or loss arising on cancellation or renewal of forward exchange contract is recognised as income or as expense for the year.

j) Retirement and other employee benefits

Retirement benefit in the form of provident fund and superannuation fund is defined contribution scheme. The contributions to the respective funds are charged to the statement of profit and loss for the year when the contributions are due. The Company has no obligation, other than the contribution payable to the respective funds.

The Company operates two defined benefit plans for its employee viz. gratuity and long term compensated absences.

Employees are entitled to benefits under the Payment of Gratuity Act, 1972, a defined benefit plan covering employees of the Company. The plan provides for a lump-sum payment to eligible employees at retirement, death, incapacitation or on termination of employment, of an amount based on the respective employee's salary and tenure of employment subject to a maximum of ₹10.00 Lakhs per employee.

Notes to Financial Statements for the year ended March 31, 2017

The gratuity liability and net periodic gratuity cost is actuarially determined based on the projected unit credit method after considering discount rates, expected long term return on plan assets and increase in compensation levels.

All actuarial gains/losses are immediately recorded to the statement of profit and loss and are not deferred.

The Company makes contributions to a fund administered and managed by Life Insurance Corporation of India ('LIC') to fund the gratuity liability. Under this scheme, the obligation to pay gratuity remains with the Company, although LIC administers the scheme.

Liability for long term compensated absences are provided for based on actuarial valuation done as per projected unit credit method.

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short-term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

The Company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for based on the actuarial valuation using the projected unit credit method at the year-end. Actuarial gains/losses are immediately taken to the statement of profit and loss and are not deferred.

k) Income taxes

Tax expense comprises of current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Indian Income Tax Act, 1961. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date.

Deferred income taxes reflect the impact of timing differences between taxable income and accounting income originating during the current year and reversal of timing differences for the earlier years. Deferred taxes are measured using the tax rates and tax laws enacted or substantially enacted at the reporting date.

Deferred tax liabilities are recognised for all taxable timing differences. Deferred tax assets are recognised for deductible timing differences only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognised only if there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits. For recognition of deferred taxes, the timing difference which originate first are considered to reverse first.

At each reporting date the Company re-assesses unrecognised deferred tax assets. It recognises unrecognised deferred tax assets to the extent that it has become reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realised.

The carrying amount of deferred tax assets are reviewed at each reporting date. The Company writes-down the carrying amount of a deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realised. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

Deferred tax assets and deferred tax liability are offset, if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred tax assets and deferred taxes relate to the same taxable entity and the same taxation authority.

MAT paid in a year is charged to statement of profit and loss as current tax. MAT credit is recognised as an asset only when and to the extent there is convincing evidence that the Company will pay normal income tax during the specified period.

The Company's bulk drugs production facility in Kullu, Himachal Pradesh, was eligible for deduction of 100% of profits until March 31, 2008 and 30% of profits from April 1, 2008 to March 31, 2013, under section 80IB of the Income Tax Act, 1961. Secondly the Company's bulk drug facility at Dahej, Gujarat, was eligible for deduction of 100% of profit until March 31, 2016 and 50% of the

Notes to Financial Statements for the year ended March 31, 2017

profits from April 1, 2016 to March 31, 2021, under section 10(AA) of the Income Tax Act, 1961. In view of such deduction, no asset has been recognized in respect of the Minimum Alternate Tax (MAT) credit available to the Company. In the year in which MAT credit becomes eligible to be recognised as an asset in accordance with recommendations contained in the Guidance Note issued by the Institute of Chartered Accountants of India, the said asset is created by way of credit to the statement of profit and loss and shown as MAT credit entitlement. The Company reviews the same at each balance sheet date and writes down the carrying amount of MAT credit entitlement to the extent there is no longer convincing evidence to the effect that Company will pay normal tax under specified period.

l) Earnings per share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The Company has not issued any potential equity shares and hence the basic earnings per share and diluted earnings per share are the same.

m) Provisions

A provision is recognised when the Company has a present obligation as a result of past event; it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on best estimate required to settle the obligation at the reporting date. These are reviewed at each reporting date and adjusted to reflect the current best estimates.

n) Contingent liabilities

Contingent asset are not recognised in the financial statement of the Company. A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

o) Leases

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased term, are classified as operating lease. Operating Lease payments are recognised as an expense in the statement of profit and loss account on a straight line basis over the lease term.

p) Cash and Cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at bank and in hand and short-term investments with an original maturity of three months or less.

q) Segment Reporting

Identification of segments :

The Company's operating businesses are organized and managed separately according to the nature of products and services provided, with each segment representing a strategic business unit that offers different products and serves different markets. The analysis of geographical segments is based on the areas in which major operating divisions of the Company operate / sell its product.

r) Borrowing costs

Borrowing cost includes interest and amortisation of ancillary costs incurred in connection with the arrangement of borrowings and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use are capitalized as part of the cost of the respective asset. All other borrowing costs are expensed in the period they occur.

Notes to Financial Statements for the year ended March 31, 2017

3. Share Capital

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Authorised shares:		
19,010,000 (2016 - 19,010,000) equity shares of ₹10 each	1,901.00	1,901.00
9,90,000 (2016 - 9,90,000) preference shares of ₹10 each	99.00	99.00
	2,000.00	2,000.00
Issued, subscribed and fully paid-up shares:		
18,192,844 (2016 - 18,192,844) equity shares of ₹10 each	1,819.28	1,819.28
Less : Amount recoverable from ESOP trust (refer note (e) below)	(48.83)	(48.83)
	1,770.45	1,770.45

a. Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

Equity shares	March 31, 2017		March 31, 2016	
	No. in Lakhs	₹ in Lakhs	No. in Lakhs	₹ in Lakhs
At the beginning of the period	181.93	1,819.28	181.93	1,819.28
Outstanding at the end of the period	181.93	1,819.28	181.93	1,819.28

b. Shares held by holding company and its ultimate holding company

Out of equity shares issued by the Company, shares held by the holding company are as follows:

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
DIL Limited, the holding company	1,276.25	1,276.25
12,762,464 (2016 - 12,762,464) equity shares of ₹ 10 each fully paid		
DVK Investment Pvt. Ltd., the ultimate holding company	8.70	8.70
87,024 (2016 - 87,024) equity shares of ₹ 10 each fully paid		

c. Terms/ rights attached to equity shares

The Company has only one class of equity shares having par value of ₹10 per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays the dividend in Indian rupees. The dividend, if any, proposed by the board of directors is subject to shareholder's approval in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be as per the terms of the Articles of Association of the Company.

d. Details of shareholders holding more than 5% shares in the Company

	March 31, 2017		March 31, 2016	
	No. in Lakhs	% holding in the class	No. in Lakhs	% holding in the class
Equity shares of ₹ 10 each fully paid				
DIL Limited	127.62	70.15%	127.62	70.15%
Evolve India Life Sciences Fund LLC	38.30	21.05%	38.30	21.05%

e. Shares reserved for issue under options

During the year ended March 31, 2011, pursuant to approval from shareholders, the Company has allotted 488,334 equity shares at face value of ₹10 each per share against cash to FBL ESOP Trust pending implementation of ESOP plan.

(No. in Lakhs)

	March 31, 2017	March 31, 2016
At the beginning of the period	4.88	4.88
Outstanding at the end of the period	4.88	4.88

Notes to Financial Statements for the year ended March 31, 2017

4. Reserve and surplus

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Capital redemption reserve	103.38	103.38
Securities premium account	1,706.46	1,706.46
General Reserve	92.32	92.32
Surplus in the statement of profit and loss		
Balance as per the last financial statements	5,378.46	4,189.54
Profit for the year	989.29	1,188.92
Net surplus in the statement of profit and loss	6,367.75	5,378.46
Total reserves and surplus	8,269.91	7,280.62

5. Long-term borrowings

(₹ in Lakhs)

	Non-Current		Current	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
Term Loans				
From bank (secured) for Dahej facility	472.62	295.57	222.19	466.67
From bank (secured) for R & D Thane	123.68	30.36	75.00	75.00
From financial institutions (secured) for Dahej facility	-	-	-	33.49
From financial institutions (secured) for R & D Thane	9.51	30.11	26.09	22.75
Vehicle Loans				
From bank (secured)	0.65	7.06	6.77	8.68
From financial institutions (secured)	-	0.24	0.22	2.38
Total	606.46	363.34	330.27	608.97
The above amount includes				
Secured borrowings	606.46	363.34	330.27	608.97
Amount disclosed under the head "other current liabilities" (refer note 9)	-	-	(330.27)	(608.97)
Net Amount	606.46	363.34	-	-

- Term loan for setting up a new facility at Dahej SEZ is taken from Union Bank of India with interest rates (BR + 4%) ranging from 13.30% to 13.60% repayable in 60 equal monthly installments. The said term loan is secured by way of first charge on fixed assets procured with financial assistance of the said term loan and by equitable mortgage of factory land and building at Dahej and Kullu.
- Term Loan for expansion of Dahej facility is taken from Union Bank of India with interest rate (BR+3.75%) ranging from 13.05% to 13.30% repayable in 48 equal monthly installments. The said term loan is secured by way of first charge on fixed assets procured with the financial assistance of the term loan and by equitable mortgage of factory land and building at Dahej and Kullu.
- Term Loan for relocation of R & D units / registered office is taken from Union Bank of India with interest rate (BR+3.75%) ranging from 13.05% to 13.30% repayable in 48 equal monthly installments. The said term loan is secured by way of first charge on fixed assets procured with the financial assistance of the term loan and by equitable mortgage of factory land and building of Dahej and Kullu.
- Term loans from financial institutions (secured) for financing the purchase of plant and machinery at Dahej SEZ and R & D Thane are taken from Siemens Financial Services Private Limited at interest rates of 13.75%, repayable in 48 equal monthly installments. The said term loans are secured by way of first charge on plant and machinery procured with financial assistance of the said term loan.
- Vehicle loans are taken from the Banks and Financial Institutions against hypothecation of the vehicles repayable in monthly installments ranging between 36 to 60 months with interest rates ranging from 10% to 14%.

Notes to Financial Statements for the year ended March 31, 2017

6. Deferred tax liability (net)

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Deferred tax liability		
Fixed assets: Impact of difference between tax depreciation and depreciation/ amortization charged for the financial reporting	651.88	600.27
Gross deferred tax liability	651.88	600.27
Deferred tax assets		
Provision for doubtful debts and advances	307.39	150.11
Provision for gratuity and long term compensated absences	72.01	50.63
Gross deferred tax assets	379.40	200.74
Net deferred tax liability	272.48	399.53

7. Provisions

(₹ in Lakhs)

	Long-Term		Short-Term	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
Provision for employee benefits				
Provision for long term compensated absences	167.27	143.76	33.74	35.18
Provision for gratuity (refer note 26 (iii))	25.18	-	-	-
Provision for tax (net)	-	-	27.98	154.80
	192.45	143.76	61.72	189.98

8. Short-term borrowings

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Cash credit from bank (secured)	1,673.31	1,489.09
Packing and post shipment credit from bank (secured)	1,132.00	1,200.62
Buyers Credit from bank (secured)	188.85	-
Buyers Credit from bank (unsecured)	368.86	-
Short term loan from holding company (unsecured) (refer note 29(d))	-	157.50
	3,363.02	2,847.21
The above amount includes		
Secured borrowings	2,994.16	2,689.71
Unsecured borrowings	368.86	157.50

Packing credit, post shipment credit, cash credit and buyers credit are from Union Bank of India and are secured against hypothecation of Company's entire stocks of raw materials, semi-finished, and finished goods, consumable stores and spares and such other moveable including book-debts, bills, whether documentary or clean, outstanding monies, receivables, and also by way of first charge on all of the Company's fixed assets both present and future. The packing credit, cash credit and buyers credit are repayable on demand. The interest rate for pre-shipment credit in foreign currency is (LIBOR+3.5%) and interest rate for export credit in rupee and cash credit is 10.8% and 13.3% respectively.

Buyers credit is taken from DBS Bank secured by lien on the deposit of ₹ 100 Lakhs. The interest rate is (LIBOR+1.65%).

Term loan from holding company includes:

Short term loan of ₹ Nil (2016 - ₹157.50 Lakhs) carrying interest @ 8% to 12% p.a., repayable on demand.

Notes to Financial Statements for the year ended March 31, 2017

9. Trade payables and other current liabilities

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Trade payables		
• total outstanding dues of micro enterprises and small enterprises (refer note 33 for details of dues to micro and small enterprises)	20.20	5.14
• total outstanding dues of creditors other than micro enterprises and small enterprises	2,699.01	1,798.42
	2,719.21	1,803.56
Other current liabilities		
Current maturities of long term borrowings (refer note 5)	330.27	608.97
Interest accrued and not due on borrowings	2.60	6.14
Statutory dues	80.04	81.53
Advance from customers	35.24	29.27
Liability for capital expenditure	155.86	98.60
Others	72.13	152.44
	676.14	976.95
	3,395.35	2,780.51

10. Property, Plant and Equipment

(₹ in Lakhs)

	Freehold land	Lease hold land	Buildings	Plant and equipment	Furniture and fixtures	Vehicles	Total
Cost							
At April 1, 2015	36.04	308.93	2,878.93	7,185.93	199.29	218.67	10,827.79
Additions	-	-	15.19	133.24	0.72	9.48	158.63
Disposals	-	-	-	18.03	-	-	18.03
At March 31, 2016	36.04	308.93	2,894.12	7,301.14	200.01	228.15	10,968.39
Additions	-	-	139.63	1,110.70	11.44	-	1,261.77
Disposals	-	-	40.92	2.72	-	23.91	67.55
At March 31, 2017	36.04	308.93	2,992.83	8,409.12	211.45	204.24	12,162.61
Depreciation							
At April 1, 2015	-	52.59	519.85	2,825.05	116.60	99.91	3,614.00
Charge for the year	-	10.83	101.35	413.08	12.35	29.73	567.34
Disposals	-	-	-	17.80	-	-	17.80
At March 31, 2016	-	63.42	621.20	3,220.33	128.95	129.64	4,163.54
Charge for the year	-	10.83	124.27	458.54	13.43	25.90	632.97
Disposals	-	-	33.00	1.67	-	22.71	57.38
At March 31, 2017	-	74.25	712.47	3,677.20	142.38	132.83	4,739.13
Net Block							
At March 31, 2016	36.04	245.51	2,272.92	4,080.81	71.06	98.51	6,804.85
At March 31, 2017	36.04	234.68	2,280.36	4,731.92	69.07	71.41	7,423.48

Notes to Financial Statements for the year ended March 31, 2017

11. Intangible assets:

(₹ in Lakhs)

	Softwares	Product Know-how	Total
Gross Block			
Cost at April 1, 2015	114.71	593.72	708.43
Additions	11.45	53.74	65.19
Disposals	-	-	-
At March 31, 2016	126.16	647.46	773.62
Additions	9.08	-	9.08
Disposals	-	-	-
At March 31, 2017	135.24	647.46	782.70
Depreciation			
At April 1, 2015	70.74	543.00	613.74
Charge for the year	18.30	61.10	79.40
Disposals	-	-	-
At March 31, 2016	89.04	604.10	693.14
Charge for the year	15.78	23.66	39.44
Disposals	-	-	-
At March 31, 2017	104.82	627.76	732.58
Net Block			
At March 31, 2016	37.12	43.36	80.48
At March 31, 2017	30.42	19.70	50.12

12. Non-current Investments

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Trade investments (valued at cost unless stated otherwise)		
Unquoted equity investments		
a) Investment in equity instruments of subsidiaries		
6,250 (2016-6,250) Equity shares of ₹10/- each in G.I Biotech Pvt. Ltd. at cost (refer note below)	0.63	0.63
220,001 (2016-220,001) Shares of G.B.Pound 1/- each in Fermenta Biotech (UK) Limited at cost	183.99	183.99
	184.62	184.62
Non-trade investments (valued at cost unless stated otherwise)		
b) Other entities		
20,000 (2016-20,000) Equity shares of ₹10/- each in Shivalik Solid Waste Management Limited	2.00	2.00
	186.62	186.62

Note:-

During the year ended March 31, 2009 the Company had entered into an agreement for transfer of the throat lozenge business along with the trademark "Astrasept" and the related movable assets for a consideration of ₹ 8.00 lakhs, to its wholly owned subsidiary G.I Biotech Private Limited (G.I). Simultaneously the Company has also entered into a share transfer agreement with Ronator Investments Limited (R.I), a Company incorporated under the legal provisions of Cyprus, to transfer its entire shareholding in G.I in four instalments to be completed by February 10, 2009 for a total consideration of USD 4.00 lakhs. In accordance with the share transfer agreement, the Company sold 3750 shares for consideration of USD 1.50 lakhs and recorded a profit of ₹ 70.60 lakhs in the year ended March 2009. The time limit stipulated for completion of the share transfer agreement and completion of transaction has been extended further to March 31, 2018.

Notes to Financial Statements for the year ended March 31, 2017

13. Long term loans and advances

(₹ in Lakhs)

	Non-Current		Current	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
Capital advances -				
Unsecured considered good	248.63	250.94	-	-
Security deposits -				
Unsecured considered good	101.95	83.88	-	-
Advances to related party (refer note 29 (d) - (11d)) * -				
Unsecured considered good	6.26	6.26	-	-
Loans and advances to employees -				
Unsecured considered good	0.85	10.00	23.97	16.49
Advance recoverable in cash or kind -				
Unsecured considered good (refer note 26 (iii))	0.06	3.65	262.63	181.20
Unsecured considered doubtful	5.08	5.08	25.86	13.68
	5.14	8.73	288.49	194.88
Provision for doubtful advance	(5.08)	(5.08)	(25.86)	(13.68)
	0.06	3.65	262.63	181.20
Others -				
Inter corporate deposits				
Doubtful	267.83	267.83	-	-
Provision for doubtful inter corporate deposit	(267.83)	(267.83)	-	-
	-	-	-	-
Advance income tax (net of provision for taxation)	-	-	6.73	86.47
Prepaid expenses	-	-	60.14	50.91
Balance with government authorities	-	-	208.64	203.05
Advance to ESOP Trust	0.27	0.27	-	-
Others	-	2.01	-	-
	358.02	357.01	562.11	538.12
* Loans and advances to related parties include				
Dues from GI Biotech Private Limited, a subsidiary of the Company	6.26	6.26	-	-

14. Trade receivables and other assets

14.1 Trade receivables

(₹ in Lakhs)

	Non-Current		Current	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
Unsecured, considered good unless stated otherwise				
Outstanding for a period exceeding six months from the date they are due for payment				
Unsecured considered good	-	-	830.84	708.09
Doubtful	589.42	176.06	-	-
	589.42	176.06	830.84	708.09
Provision for doubtful receivables	(589.42)	(176.06)	-	-
	-	-	830.84	708.09
Other receivables				
Unsecured considered good	-	-	3,631.35	3,630.20
	-	-	4,462.19	4,338.29

Notes to Financial Statements for the year ended March 31, 2017

14. Trade receivables and other assets (Contd.)

(₹ in Lakhs)

	Non-Current		Current	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
Trade receivables include :-				
I) Dues from a Company in which the Company's director is a director - Dupen Laboratories Private Limited (refer note 29 (d) - (11e))	-	-	-	4.14
II) Dues from holding company - DIL Ltd. (refer note 29 (d) - (11e))	-	-	0.22	9.95

14.2 Other Assets

(₹ in Lakhs)

	Non-Current		Current	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
Unsecured, considered good unless stated otherwise				
Bank balance (refer note 16)	-	0.70	153.71	68.68
Export incentives receivable	-	-	326.30	216.67
Others	-	-	1.23	79.34
	-	0.70	481.24	364.69

15. Inventories (valued at lower of cost and net realizable value)

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Raw materials and packing materials (include stock in transit of ₹50.82 Lakhs (2016 ₹ 78.51 Lakhs)) (refer note 19)	1,948.56	1,392.24
Work in progress (refer note 20)	1,425.18	777.00
Finished goods (refer note 20)	319.36	178.10
Stores and spares	181.49	136.44
	3,874.59	2,483.78

16. Cash and bank balances

(₹ in Lakhs)

	Non-Current		Current	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
Cash and cash equivalents				
Balances with banks :				
- On current accounts	-	-	108.04	80.82
- Deposits with original maturity of less than three months	-	-	0.03	0.03
Cash on hand	-	-	6.42	3.64
Other bank balances				
Margin money deposits*	-	-	153.71	68.68
Deposits with original maturity of more than twelve months	-	0.70	-	-
	-	0.70	268.20	153.17
Amount disclosed under other assets (refer note 14.2)	-	(0.70)	(153.71)	(68.68)
	-	-	114.49	84.49

* Margin money deposits with a carrying amount of ₹153.71 lakhs (2016 ₹ 68.68 lakhs) are subject to first charge to secure the letters of credit facilities availed by the Company.

Notes to Financial Statements for the year ended March 31, 2017

17. Revenue from operations

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Revenue from operations		
Sale of products		
Finished goods	15,689.37	14,419.07
Traded goods	35.76	218.52
Sale of services	5.76	19.78
Other operating revenue		
Scrap sales	5.86	4.76
Insurance Claim	-	39.19
Exports Incentive	341.65	303.04
Revenue from operations (gross)	16,078.40	15,004.36
Less: Excise duty #	155.89	294.77
Revenue from operations (net)	15,922.51	14,709.59

Excise duty on sales amounting to ₹ 155.89 lakhs (2016 ₹ 294.77 lakhs) has been reduced from sales in statement of profit and loss and excise duty on increase/(decrease) in stock amounting to (₹ 12.32 lakhs) (2016 ₹ 24.39 lakhs) has been considered as expenses in note 24 of the financial statements.

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Details of product sold		
Finished goods sold		
Vitamin D3 Product range	10,883.36	10,462.54
Silicon dry powder	498.89	383.73
Phenyramidol Hcl	3,353.78	2,329.07
Fermsept	146.58	95.33
Biocatalyst and Enzymes	530.94	863.43
Others	275.82	284.97
	15,689.37	14,419.07
Traded goods sold		
Granules	-	77.58
Injections	30.58	33.14
Spray	5.18	107.80
	35.76	218.52
	15,725.13	14,637.59
Details of service rendered		
Environmental project consultancy fees	5.76	19.78
	5.76	19.78

18. Other Income

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Interest Income on		
Bank deposits	8.73	3.14
Others	14.81	2.52
Foreign exchange fluctuation gain (net)	206.68	258.32
Profit on Sale of fixed assets (net)	-	0.70
Dividend Income	0.20	0.20
Other non-operating income	1.94	4.65
	232.36	269.53

Notes to Financial Statements for the year ended March 31, 2017

19. Cost of raw materials and packing materials consumed

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Inventories of raw materials / packing materials at the beginning of the year	1,392.24	1,035.12
Add : Purchases	8,155.62	6,641.95
	9,547.86	7,677.07
Less : Inventories of raw materials / packing materials at the end of the year	1,948.56	1,392.24
Cost of raw materials and packing materials consumed	7,599.30	6,284.83
Details of raw materials and packing materials consumed		
Cholesterol	3,902.56	3,131.20
Lithium Amide	544.60	331.65
2-Amino Pyridine	326.04	219.53
Iso Propyl Alcohol	242.83	160.42
Denatured Spirit	226.87	181.64
Styrene Oxide	227.36	157.81
Dimethyl formamide	120.05	91.19
Acetone	185.88	145.52
Petroleum Ether	305.61	244.64
Calcium Dibasic Phosphphate	263.62	200.89
Other materials	1,253.88	1,420.34
	7,599.30	6,284.83
Details of Raw materials and packing materials inventory		
Cholesterol	228.06	494.38
Pyridine styrene oxide derivative	103.25	69.47
Lithium Amide	65.96	51.71
2- Amino Pyridine	45.00	42.64
Woolgrease	108.81	115.82
Methyl Formate	3.69	3.61
Collidine	6.91	1.63
Dibromo Dimethyl Hydantion	4.14	4.96
Others	1,382.74	608.02
	1,948.56	1,392.24
Details of purchase of traded goods		
Granules	-	46.50
Injections	18.24	19.84
Spray	3.97	93.77
	22.21	160.11

Notes to Financial Statements for the year ended March 31, 2017

20. (Increase)/decrease in inventories

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Inventories at the end of the year (refer note 15)		
Work in progress	1,425.18	777.00
Finished goods	319.36	178.10
	1,744.54	955.10
Inventories at the beginning of the year		
Work in progress	777.00	810.41
Finished goods	178.10	91.63
	955.10	902.04
	(789.44)	(53.06)
Details of inventory		
Work in progress		
Vitamin D3 Product range	1,255.67	653.19
Silicon dry powder	12.95	1.46
Phenylramidol Hcl	13.83	8.17
Biocatalyst and Enzymes	8.39	15.41
Others	134.34	98.77
	1,425.18	777.00
Finished goods		
Vitamin D3 Product range	243.66	99.96
Silicon dry powder	-	2.90
Biocatalyst and Enzymes	52.78	47.59
Others	22.92	27.65
	319.36	178.10

21. Employee benefit expense

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Salaries, wages and bonus	1,824.42	1,711.61
Contribution to provident and other fund	102.28	93.35
Gratuity expense (refer note 26 (iv))	56.61	21.34
Staff welfare expenses	276.05	209.98
	2,259.36	2,036.28

22. Depreciation and amortisation expense

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Depreciation of Property, Plant and Equipment	632.97	567.34
Amortisation of intangible assets	39.44	79.40
	672.41	646.74

23. Finance Costs

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Interest:		
- On term loans	98.38	89.91
- On Working Capital	234.97	302.39
- On Short term loan from holding company	5.96	3.13
- Others	23.03	59.19
	362.34	454.62

Notes to Financial Statements for the year ended March 31, 2017

24. Other Expenses

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Manufacturing Expense		
Excise duty other than recovered on sales	10.59	59.39
Labour charges	302.94	249.91
Power, fuel and gas	829.37	774.72
Processing charges	595.31	445.12
Repairs to building	43.65	52.60
Repairs to machinery	76.20	64.16
Stores and spare parts consumed	638.56	468.07
Water charges	13.26	12.63
Sub total (i)	2,509.88	2,126.60
Selling and distribution expenses		
Advertising and sales promotions	103.09	104.58
Freight and forwarding charges	294.31	255.19
Sales commission	126.86	147.33
Sub total (ii)	524.26	507.10
Administration and other expenses		
Rent (refer note 27)	123.56	111.60
Repairs and maintenance - others	146.39	100.41
Insurance	73.90	62.36
Rates and taxes	79.81	78.88
Provision for doubtful debts and advances (net)	425.54	9.63
Directors sitting fee	2.00	4.25
Travelling and conveyance	332.39	313.91
Professional and legal fees	215.55	232.46
Payment to auditors (Refer details below)	27.18	26.34
Postage and telephone	35.77	31.00
Printing & stationery	69.53	53.23
Staff recruitment expenses	28.51	16.17
Loss on sale of fixed assets (net)	9.05	-
Donations (refer note 39)	16.37	14.01
Bank charges	47.48	39.90
Miscellaneous expenses	132.81	104.21
Sub total (iii)	1,765.84	1,198.36
Total (i+ii+iii)	4,799.98	3,832.06

Payment to auditors

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
As Auditor		
Audit fee	13.00	14.00
Tax audit fee*	4.60	3.10
Limited review	7.50	7.50
Certification fees	0.50	0.50
Reimbursement of expense*	1.58	1.24
	27.18	26.34

* includes amount paid to the auditors other than statutory auditors

Notes to Financial Statements for the year ended March 31, 2017

25. Earnings per share (EPS)

The following reflects the profit and share data used in the basic and diluted EPS computations:

	(₹ in Lakhs)	
	March 31, 2017	March 31, 2016
Net profit for calculating basic and diluted EPS	989.29	1,188.92
	(No. of Shares)	
Weighted average number of equity shares in calculating basic and diluted EPS	18,192,844	18,192,844
Earnings per equity share (nominal value of share ₹ 10) (2016: ₹ 10)	5.44	6.54

26. Employee benefits

The Company operates two employee benefit plans

I Defined contribution plan which includes contribution to provident and superannuation fund

II Defined benefit plan which includes gratuity (funded) and long term compensated absences (unfunded)

	(₹ in Lakhs)	
	As at March 31, 2017	As at March 31, 2016
Defined Contribution Plan		
Contribution to Defined Contribution Plan recognised in the statement of profit and loss under employee benefit expenses on note 21 for the year are as under-		
Employer's contribution to provident fund	101.10	92.21
Employer's contribution to superannuation fund	1.18	1.14

Defined Benefit Plan

The Company operates two defined plans, viz. gratuity and long term compensated absences benefit plans, for its employees. Under the gratuity plan, every employee who has completed at least five years of service gets a gratuity on departure at 15 days of last drawn salary for each completed year of service. The scheme is funded with Life Insurance Corporation of India.

Gratuity as per actuarial valuation

	(₹ in Lakhs)	
	Gratuity Funded	
	As at March 31, 2017	As at March 31, 2016
i) Changes in the present value of the defined benefit obligation		
Opening	157.80	128.42
Interest cost	12.53	10.98
Current service cost	18.34	17.10
Benefits paid	(21.54)	(4.48)
Net actuarial (gain) / loss	47.51	5.78
Closing	214.64	157.80
ii) Changes in fair value of plan assets		
Opening	161.45	134.89
Expected return on plan assets	12.40	12.20
Net actuarial gain/ (loss)	9.37	0.32
Employer's contribution	27.78	18.52
Benefits paid	(21.54)	(4.48)
Closing	189.46	161.45

Notes to Financial Statements for the year ended March 31, 2017

26. Employee benefits (Contd.)

(₹ in Lakhs)

	Gratuity Funded	
	As at March 31, 2017	As at March 31, 2016
iii) Amounts recognised in balance sheet		
Present value of defined benefit obligation	214.64	157.80
Fair value of plan assets	189.46	161.45
Net liability / (assets) recognized in balance sheet (refer note 7 and note 13)	25.18	(3.65)
iv) Amounts recognised in statement of profit and loss		
Interest cost	12.53	10.98
Current service cost	18.34	17.10
Expected return on plan assets	(12.40)	(12.20)
Net actuarial (gain) / loss recognised	38.14	5.46
Gratuity expense (refer note 21)	56.61	21.34
v) Actual return on plan assets	21.77	12.52
vi) Principal assumptions used in actuarial valuation		
Discount rate	7.00%	7.85%
Expected return on plan assets	7.50%	8.00%
Salary escalation rate	7.00%	5.00%
Withdrawal rate (as per age group)	21 to 30 - 10%	21 to 30 - 10%
	31 to 40 - 5%	31 to 40 - 5%
	41 to 50 - 3%	41 to 50 - 3%
	51 to 57 - 2%	51 to 57 - 2%
vii) Investments with insurers	96.00%	99.00%
Investments with others	4.00%	1.00%

(₹ in Lakhs)

	Gratuity Funded as at				
	March 31, 2017	March 31, 2016	March 31, 2015	March 31, 2014	March 31, 2013
viii) Amounts for the current and previous four periods are as under:-					
Defined benefit obligations	214.64	157.80	128.42	151.28	144.39
Plan assets	189.46	161.45	134.89	141.79	132.81
Surplus/(Deficit)	(25.18)	3.65	6.47	(9.49)	(11.58)
Experience adjustments on plan liabilities	9.19	5.22	2.68	(11.58)	(12.62)
Experience adjustments on plan assets	9.37	0.32	(2.15)	(2.57)	0.80

- ix) a The discount rate is considered based on market yield on government bonds having currency and terms consistent with the currency and terms of post-employment benefit obligations.
- b Expected rate of return on assets assumed by the insurance company is generally based on their investment pattern as stipulated by the Government of India.
- c The estimates of rate escalation in salary considered in the actuarial valuation take into account inflation, seniority, promotion and other relevant factors including supply demand in the employment market.
- d The Company expects to contribute ₹20 lakhs to the Gratuity fund in 2017-18. (2016 - ₹20 lakhs)

Notes to Financial Statements for the year ended March 31, 2017

27. The Company has entered into arrangements for taking on leave and license basis certain office premises and guest houses. The agreements are cancellable having escalation clause and are renewable.

(₹ in Lakhs)

	Year ended March 31, 2017	Year ended March 31, 2016
a) Lease payments recognized in the statement of profit and loss for the year.	123.56	111.60
b) Future minimum lease payments under the leases in the aggregate and for each of the following periods:		
Not later than one year	94.67	47.75
Later than one year and not later than five years	122.59	62.70

28. Segment Information:

- a Primary segment – The Company has identified chemical, bulk drug & enzymes as the only primary reportable segment
b Secondary segments – Geographical segments

(₹ in Lakhs)

	Year ended March 31, 2017	Year ended March 31, 2016
Segment revenue from external customers, based on geographical location of customers (Sales)		
India	3,982.84	4,611.05
Europe	9,093.69	8,010.70
Others	2,845.98	2,087.84
TOTAL	15,922.51	14,709.59
Assets and additions to property, plant & equipment and intangible assets		
Segment assets		
India	14,557.84	12,438.17
Europe	2,386.00	2,525.90
Others	988.00	811.33
TOTAL	17,931.84	15,775.40
Capital Expenditure (including capital work in progress)		
India	1,093.89	819.19
Europe	-	-
Others	-	-
TOTAL	1,093.89	819.19

Note:

The operating facilities of the Company are commonly employed for both the domestic and export business, hence it is not possible to report segment result/liabilities by geographical segment.

Notes to Financial Statements for the year ended March 31, 2017

29. Related party disclosure:

- a) Parties where control exists

Holding company:-

DIL Limited

Subsidiaries:-

a) Fermenta Biotech (UK) Limited

b) G.I. Biotech Pvt Limited

- b) Related party relationships where transactions have taken place during the year:-

Key Management Personnel

Mr. Satish Varma - Managing Director

Ms. Anupama Datla Desai – Executive Director

Mr. Prashant Nagre - Chief Executive Officer

Mr. Kapil Gohil - Chief Financial Officer

Mr. Sanjay Basantani - Company Secretary (up to 8th February 2017)

Mr. Varadvinayak Khambete - Company Secretary (From 27th February 2017)

Enterprises owned or significantly influenced by key management personnel or their relatives:-

Dupen Laboratories Pvt Limited.

Lacto Cosmetics (Vapi) Pvt. Limited.

- c) An individual directly controlling the holding company, namely DIL Limited and can exercise significant influence:-
Mr. Krishna Datla – Director

- d) Transactions with related parties

Following table provides the total amount of transactions that have been entered into with related parties for the relevant financial year.

(₹ in Lakhs)

Sr. No.	Particulars	Holding Company	Subsidiaries	Key Management Personnel	Enterprises owned or significantly influenced by key management personnel or their relatives.
1	Sales				
	Dupen Laboratories Pvt Ltd.				-
					(14.16)
2	Purchase of raw materials and services				
	Dupen Laboratories Pvt Limited.				9.49
					(7.64)
	Lacto Cosmetics (Vapi) Pvt. Ltd.				5.54
					(5.54)
3	Interest on loan taken	5.96			
		(16.90)			
4	Rent paid	53.20			
		(82.13)			
5	Processing Charges Paid				
	Lacto Cosmetics (Vapi) Pvt. Ltd.				10.66
					(7.20)

Notes to Financial Statements for the year ended March 31, 2017

29. Related party disclosure: (Contd.)

d) Transactions with related parties

Following table provides the total amount of transactions that have been entered into with related parties for the relevant financial year.

(₹ in Lakhs)

Sr. No.	Particulars	Holding Company	Subsidiaries	Key Management Personnel	Enterprises owned or significantly influenced by key management personnel or their relatives.
6	Company's share of expenses paid	33.56 (45.27)			
7	Other reimbursements received	0.76 (11.66)			
8	Loan repaid	157.50 (65.00)			
9	Liability written back	- (10.00)			
10	Remuneration to key management personnel.*				
	Ms. Anupama Datla Desai			58.55 (75.02)	
	Mr. Satish Varma			74.43 (88.44)	
	Mr. Prashant Nagre			89.16 (87.27)	
	Mr. Kapil Gohil			39.31 (31.45)	
	Mr. Sanjay Basantani			16.45 (16.94)	
	Mr. Varadvinayak Khambete			0.91 -	
	Directors sitting fees				0.85 (1.55)
11	Balance outstanding as at the year end				
	a. Loan payable (refer note 8)	- (157.50)			
	b. Trade Payable				
	DIL Ltd.	3.08 (3.24)			
	Lacto Cosmetics (Vapi) Pvt. Ltd.				3.18 (4.23)
	Dupen Laboratories Pvt Ltd				3.50 (8.58)

Notes to Financial Statements for the year ended March 31, 2017

29. Related party disclosure: (Contd.)

(₹ in Lakhs)

Sr. No.	Particulars	Holding Company	Subsidiaries	Key Management Personnel	Enterprises owned or significantly influenced by key management personnel or their relatives.
c.	Other current liabilities				
	Ms. Anupama Datla Desai - Salary, bonus and con. to PF			- (23.33)	
	Mr. Satish Varma - Salary, bonus and con. to PF			- (23.33)	
	Mr. Prashant Nagre - Salary, bonus and con. to PF			7.91 (14.39)	
	Mr. Kapil Gohil - Salary, bonus and con. to PF			1.65 (3.00)	
	Mr. Sanjay Basantani - Salary, bonus and con. to PF			- (1.60)	
	DIL Ltd. (refer note 9)	- (2.83)			
d.	Long term loans and advances				
	G.I. Biotech Pvt Ltd. (refer note 13)		6.26 (6.26)		
e.	Trade receivables				
	DIL Ltd. (refer note 14.1)	0.22 (9.95)			
	Dupen Laboratories Pvt Ltd. (refer note 14.1)				- (4.14)

(Figures in brackets are the corresponding figures in respect of the previous year).

* Note: The remuneration to the key managerial personnel includes salary, bonus, contribution to PF and commission, if any, and does not include the provisions made for gratuity and leave benefits, as they are determined on an actuarial basis for the Company as a whole.

30. Capital and other commitments

- a) Estimated amounts of contracts remaining to be executed on capital account and not provided for (net of advances) is ₹296.46 lakhs (2016 ₹ 526.52 lakhs).

31. Contingent liabilities

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Claims against the Company not acknowledged as debts		
a Tax matters		
- Excise Duty - matter under appeal	-	8.00
b Other claims	94.26	54.99

Notes to Financial Statements for the year ended March 31, 2017

32. Derivative instruments and un-hedged foreign currency exposure

a) Particulars of "un-hedged foreign currency exposure" as at March 31, 2017

Particulars	Currency	March 31, 2017		March 31, 2016	
		Amount (Foreign Currency in Millions)	Amount (₹ in Lakhs)	Amount (Foreign Currency in Millions)	Amount (₹ in Lakhs)
Trade receivables	Dollar - \$	1.61	1,039.72	0.87	572.99
	Euro - €	3.45	2,400.81	2.95	2,204.80
Trade payables	Dollar - \$	0.11	74.34	0.37	244.97
	Euro - €	1.19	830.21	0.46	347.33
	Pound - £	-	0.72	0.00	0.69
PCFC	Euro - €	1.63	1,132.00	0.80	601.09
EEFC	Euro - €	0.00	0.28	0.00	0.30
Buyers Credit	Dollar - \$	0.57	368.86	-	-
	Euro - €	0.27	188.85	-	-

33. Details of dues to micro and small enterprises as per MSMED Act, 2006

(₹ in Lakhs)

Particulars	March 31, 2017	March 31, 2016
a) (i) Principal amount remaining unpaid to any supplier at the end of the accounting year	20.20	5.14
(ii) Interest due on above	0.57	0.10
Total of (i) & (ii)	20.77	5.24
b) The amount of interest paid by the buyer in terms of Section 16 of the Micro, Small and Medium Enterprise Development Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	-	-
c) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under Micro, Small and Medium Enterprise Development Act, 2006	-	-
d) The amount of interest accrued and remaining unpaid at the end of each accounting year; and	-	-
e) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under Section 23 of the Micro, Small and Medium Enterprise Development Act, 2006	-	-

34. C.I.F Value of imports:

(₹ in Lakhs)

	Year ended March 31, 2017	Year ended March 31, 2016
Raw materials and packing materials	4,369.23	3,847.03
Stores and spare parts	64.10	14.70
Capital goods	50.18	46.02
	4,483.51	3,907.75

Notes to Financial Statements for the year ended March 31, 2017

35. Expenditure in foreign currency (accrual basis)

(₹ in Lakhs)

	Year ended March 31, 2017	Year ended March 31, 2016
Professional fees	81.60	69.79
Travelling	36.97	33.01
Commission	68.83	23.75
Foreign Advertisement and trade exhibition	32.17	14.36
Analytical fees	17.83	-
Patent & Trademark	2.61	3.04
Rates and Taxes	1.41	4.09
Others	19.32	34.27
	260.74	182.31

36. Imported and indigenous raw materials, components and spare parts consumed

(₹ in Lakhs)

	Year ended March 31, 2017		Year ended March 31, 2016	
	%	₹ in Lakhs	%	₹ in Lakhs
Raw materials and packing materials consumed:				
Imported	61%	4,613.88	62%	3,888.41
Indigenous	39%	2,985.42	38%	2,396.42
	100%	7,599.30	100%	6,284.83
Stores and spare parts				
Imported	8%	51.17	10%	47.15
Indigenous	92%	587.39	90%	420.92
	100%	638.56	100%	468.07

37. Earnings in foreign currency

(₹ in Lakhs)

	Year ended March 31, 2017	Year ended March 31, 2016
F. O. B. value of exports	11,777.18	9,902.42
Freight and insurance on exports	162.49	196.12

38. Research and Development Expenditure

During the year, research and development expenditure of ₹ 507.74 Lakhs (2016 - ₹ 366.66 Lakhs) (excluding interest and depreciation) has been charged to the statement of profit and loss. The capital expenditure in the current year on research and development amounts to ₹195.65 Lakhs (2016 - ₹ 3.22 Lakhs).

39. Details of CSR expenditure

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
a) Gross amount required to be spent by the Company during the year	19.35	10.83

(₹ in Lakhs)

Particulars	In cash	Yet to be paid in cash	Total
b) Amount spent during the year ending on 31st March, 2017:			
i) Construction/acquisition of any asset	-	-	-
ii) On purposes other than (i) above	8.29	-	8.29
c) Amount spent during the year ending on 31st March, 2016:			
i) Construction/acquisition of any asset	-	-	-
ii) On purposes other than (i) above	1.90	-	1.90

Notes to Financial Statements for the year ended March 31, 2017

40. Capitalisation of Expenditure

During the year, the Company has capitalized the following expenses of revenue nature to the cost of property, plant & equipment /capital work-in-progress (CWIP). Consequently, expenses disclosed under the respective notes are net of amounts capitalized by the Company.

(₹ in Lakhs)

	March 31, 2017	March 31, 2016
Finance Costs	59.22	8.93
	59.22	8.93

41. Specified bank notes

(Amt in Rupees)

Particulars	SBNs #	Other denomination notes	Total
Closing Cash in hand as on 8.11.2016	1,211,000	91,407	1,302,407
(+) Withdrawal from Bank account	-	1,208,000	1,208,000
(-) Paid for permitted payments	-	(1,198,022)	(1,198,022)
(-) Amount deposited in banks	(1,211,000)	-	(1,211,000)
Closing Cash in hand as on 30.12.2016	-	101,385	101,385

For the purpose of this clause, the term 'Specified Bank Notes' shall have the same meaning provided in the notification of Government of India, in the Ministry of Finance, Department of Economic Affairs number S.O. 3407 (E), dated November 08, 2016.

42. Prior year amounts have been regrouped / reclassified where necessary to conform with current year's classification.

As per our report of even date

For S R B C & CO LLP
ICAI Firm Registration Number: 324982E / E300003
Chartered Accountants

per Vikram Mehta
Partner
Membership No.: 105938

Place: Mumbai
Date : May 30, 2017

For and on behalf of the Board of Directors of
Fermenta Biotech Limited

Peter Bains Chairman	Satish Varma Managing Director	Krishna Datla Director
Sanjay Buch Director	Anupama Datla Desai Executive Director	Viswanath Chibrolu Director
Gopakumar Nair Director	Varadvinayak Khambete Company Secretary	Kapil Gohil Chief Financial Officer

Place: Thane
Date : May 30, 2017